Wisconsin Alumni Research Foundation

Qolab mission is to build high quality qubits by leveraging the most advanced semiconductor manufacturing processes.

Leo Cancer Care is focused on revolutionizing cancer radiation therapy by offering a treatment system designed to enhance patient experience and outcomes. Founded in Australia, the company leverages global research that highlights the benefits of upright patient positioning during treatment. This innovative approach shifts the traditional paradigm of machine rotation to patient rotation, allowing for a more controlled and efficient therapy process. The system integrates advanced 3D imaging and precise radiation beam management, ensuring that the appropriate amount of energy is delivered to targeted tissues. By streamlining cancer treatment and connecting patients to centralized care centers, Leo Cancer Care aims to reduce both the physical discomfort and costs typically associated with chemotherapy and radiation therapy, ultimately putting patients in control of their treatment journey.

Ubicept is a company focused on computer vision technology, specializing in the development of advanced image sensors that enhance the capabilities of computer vision algorithms. Their offerings include photon-counting cameras and edge photon processing solutions, which are designed to capture motion effectively. Ubicept's technology is applicable across various sectors, including mobility, robotics, aerospace, and smart manufacturing, allowing clients to perceive and interpret their environments safely and accurately. Additionally, the company provides a private developer portal to support the integration and implementation of their machine learning services.

Realta Fusion is focused on developing fusion energy technology aimed at producing industrial heat and power. The company leverages advancements in superconducting materials, plasma physics, and computing power to create a straightforward linear fusion reactor design. This innovative approach allows Realta Fusion to utilize abundant fuel sources, offering a zero-carbon solution for heat and power generation. By minimizing capital expenditures associated with power plant construction, the company positions itself as a provider of sustainable energy solutions.

Pyran LLC, based in Madison, Wisconsin, specializes in the development of 1,5-pentanediol, an environmentally friendly compound derived from renewable wood and crop waste resources, such as corn cobs. Founded in 2017, the company serves the chemical industry by providing a sustainable alternative to traditional petroleum-based chemicals. Pyran's diol product is utilized as a raw material in the production of various everyday materials, including paints, coatings, adhesives, biodegradable films, and plastics. By offering renewable five-carbon products, the company enables clients to access higher-performing and cost-effective materials while addressing the challenges posed by diminishing natural resources and climate change.

Immuto Scientific is a biotechnology services company that specializes in providing analytical insights to pharmaceutical firms involved in drug discovery. The company has developed a protein footprinting technology that automates complex protein analysis, significantly enhancing the efficiency of the drug development process for protein therapeutics. This technology offers a faster alternative to traditional methods for protein structure analysis, allowing drug developers to determine protein structures more quickly and effectively, thereby streamlining the overall drug discovery process.

Pyran LLC, based in Madison, Wisconsin, specializes in the development of 1,5-pentanediol, an environmentally friendly compound derived from renewable wood and crop waste resources, such as corn cobs. Founded in 2017, the company serves the chemical industry by providing a sustainable alternative to traditional petroleum-based chemicals. Pyran's diol product is utilized as a raw material in the production of various everyday materials, including paints, coatings, adhesives, biodegradable films, and plastics. By offering renewable five-carbon products, the company enables clients to access higher-performing and cost-effective materials while addressing the challenges posed by diminishing natural resources and climate change.

Leo Cancer Care is focused on revolutionizing cancer radiation therapy by offering a treatment system designed to enhance patient experience and outcomes. Founded in Australia, the company leverages global research that highlights the benefits of upright patient positioning during treatment. This innovative approach shifts the traditional paradigm of machine rotation to patient rotation, allowing for a more controlled and efficient therapy process. The system integrates advanced 3D imaging and precise radiation beam management, ensuring that the appropriate amount of energy is delivered to targeted tissues. By streamlining cancer treatment and connecting patients to centralized care centers, Leo Cancer Care aims to reduce both the physical discomfort and costs typically associated with chemotherapy and radiation therapy, ultimately putting patients in control of their treatment journey.

OnLume, Inc. is a medical device company based in Madison, Wisconsin, focused on developing innovative solutions for fluorescence image-guided surgery. Founded in 2015, the company aims to enhance surgical precision and patient outcomes by providing surgeons with high-quality imaging in well-lit environments, applicable to both human and veterinary medicine. Their technology allows for improved visualization of critical anatomy in real-time during surgical procedures while using low concentrations of fluorescent agents to minimize post-surgical complications. Currently, OnLume is testing prototypes in collaboration with the Laboratory for Optical and Computational Imaging at the University of Wisconsin and the Morgridge Institute for Research. The company's systems have not yet received FDA clearance for market entry and are not available for sale.

Stuart Therapeutics is a biotechnology company focused on developing PolyCol, a therapeutic platform designed for various ophthalmic conditions. This innovative platform utilizes a synthesized peptide to repair disease-damaged helical collagen in the eye, promoting accelerated healing of epithelial cells, restoring nerve function, and reducing inflammation. PolyCol addresses several ophthalmic indications, including dry eye disease, dry age-related macular degeneration, and glaucoma. The technology is rooted in patented research from a prominent U.S. university and is supported by additional intellectual property acquired by the company. In addition to ophthalmic applications, Stuart Therapeutics is exploring the use of PolyCol for gastrointestinal, inflammatory, and oncology conditions, aiming to provide new treatment options across a range of medical fields.

LÜM is a startup based in Madison that operates a music discovery and streaming platform combined with a social network. The platform is designed to promote emerging artists, enabling them to grow their fan bases while shifting the focus away from established talents. LÜM aims to enhance the music experience by introducing blockchain technology and NFTs, which will allow over 10,000 artists to engage with fans through NFT Access Passes. This initiative seeks to empower artists by restoring value to their work and redefining the fan-to-artist relationship. By facilitating a more equitable environment for music discovery and monetization, LÜM aspires to decrease the disparity in exposure between mainstream and new music, supporting artists throughout their careers.

LÜM is a startup based in Madison that operates a music discovery and streaming platform combined with a social network. The platform is designed to promote emerging artists, enabling them to grow their fan bases while shifting the focus away from established talents. LÜM aims to enhance the music experience by introducing blockchain technology and NFTs, which will allow over 10,000 artists to engage with fans through NFT Access Passes. This initiative seeks to empower artists by restoring value to their work and redefining the fan-to-artist relationship. By facilitating a more equitable environment for music discovery and monetization, LÜM aspires to decrease the disparity in exposure between mainstream and new music, supporting artists throughout their careers.

PROMISS Diagnostics specializes in developing innovative, non-invasive diagnostic tools aimed at early detection of ovarian cancer. The company's core product is a machine-learning-based clinical test kit that utilizes a proprietary algorithm analyzing various parameters such as calcium levels, albumin, age, and menopause status. This approach allows the test to generate a concise score indicating the presence of cancerous masses in the ovary, facilitating early diagnosis for clinicians. PROMISS Diagnostics is committed to making these advanced diagnostic solutions both efficient and affordable, striving to improve accessibility for patients and enhance clinical outcomes in cancer detection.

SimpleMachines, Inc. is a semiconductor design and development company based in Madison, Wisconsin, established in 2016. It specializes in creating a Software-Defined Compute platform that addresses the evolving demands of artificial intelligence, virtual reality, machine learning, robotics, and big data. As traditional computing systems face limitations due to the end of Moore's Law and the increasing complexity of software, SimpleMachines offers a programmable platform that allows for real-time hardware optimization. This innovative approach contrasts with conventional single-purpose systems, which are costly, time-consuming to develop, and often become obsolete upon deployment. The company's platform enables software developers to enhance application performance by dynamically reconfiguring hardware, thus supporting a wide range of use cases and ensuring adaptability in rapidly changing technological environments.

HealthMyne, Inc. is a healthcare informatics company based in Madison, Wisconsin, established in 2013. It specializes in providing innovative imaging solutions and analytics primarily for cancer care providers. The company's technology enhances clinical decision-making by offering real-time, evidence-based imaging insights that facilitate improved patient care while also reducing delivery costs. HealthMyne's platform includes features such as tumor image manipulation, automatic tumor staging, specialized reporting, and management of incidental findings, all aimed at streamlining clinical workflows. By integrating electronic health records and image repositories, HealthMyne supports physicians in diagnosing and treating patients more effectively, ultimately enhancing clinical collaboration and quality assurance in patient management.

SimpleMachines, Inc. is a semiconductor design and development company based in Madison, Wisconsin, established in 2016. It specializes in creating a Software-Defined Compute platform that addresses the evolving demands of artificial intelligence, virtual reality, machine learning, robotics, and big data. As traditional computing systems face limitations due to the end of Moore's Law and the increasing complexity of software, SimpleMachines offers a programmable platform that allows for real-time hardware optimization. This innovative approach contrasts with conventional single-purpose systems, which are costly, time-consuming to develop, and often become obsolete upon deployment. The company's platform enables software developers to enhance application performance by dynamically reconfiguring hardware, thus supporting a wide range of use cases and ensuring adaptability in rapidly changing technological environments.

FluGen, Inc. is a biopharmaceutical company focused on the prevention and treatment of influenza and other respiratory pathogens. Founded in 2007 and based in Madison, Wisconsin, FluGen develops vaccines to combat seasonal and pandemic influenza. Its primary product, RedeeFlu, is a nasal spray vaccine designed to protect against influenza, utilizing a live, single replication virus that has a portion of the M2 segment deleted. This innovative approach allows for effective prevention of influenza and supports healthcare professionals in controlling potential pandemics. The company is actively engaged in clinical-stage vaccine development to address both seasonal influenza and emerging respiratory threats.

Isomark, LLC, founded in 2005 and based in Madison, Wisconsin, specializes in non-invasive breath monitoring technology aimed at detecting life-threatening infections in both humans and animals. The company has developed a patented breath analyzer called Canary, which measures and analyzes isotopic biomarkers in exhaled CO2 samples. This technology enables rapid detection of infections, providing results in as little as 30 seconds, significantly faster than traditional diagnostic methods that may take hours or days. In the agricultural sector, Isomark addresses the pressing issue of bovine respiratory diseases, which affect approximately one million beef cattle annually in the United States, leading to substantial economic losses. By offering real-time monitoring at the Chute site, Isomark's technology enhances animal health management, reduces the need for antibiotics, and ultimately improves meat quality for consumers.

HealthMyne, Inc. is a healthcare informatics company based in Madison, Wisconsin, established in 2013. It specializes in providing innovative imaging solutions and analytics primarily for cancer care providers. The company's technology enhances clinical decision-making by offering real-time, evidence-based imaging insights that facilitate improved patient care while also reducing delivery costs. HealthMyne's platform includes features such as tumor image manipulation, automatic tumor staging, specialized reporting, and management of incidental findings, all aimed at streamlining clinical workflows. By integrating electronic health records and image repositories, HealthMyne supports physicians in diagnosing and treating patients more effectively, ultimately enhancing clinical collaboration and quality assurance in patient management.

Isomark, LLC, founded in 2005 and based in Madison, Wisconsin, specializes in non-invasive breath monitoring technology aimed at detecting life-threatening infections in both humans and animals. The company has developed a patented breath analyzer called Canary, which measures and analyzes isotopic biomarkers in exhaled CO2 samples. This technology enables rapid detection of infections, providing results in as little as 30 seconds, significantly faster than traditional diagnostic methods that may take hours or days. In the agricultural sector, Isomark addresses the pressing issue of bovine respiratory diseases, which affect approximately one million beef cattle annually in the United States, leading to substantial economic losses. By offering real-time monitoring at the Chute site, Isomark's technology enhances animal health management, reduces the need for antibiotics, and ultimately improves meat quality for consumers.

FluGen, Inc. is a biopharmaceutical company focused on the prevention and treatment of influenza and other respiratory pathogens. Founded in 2007 and based in Madison, Wisconsin, FluGen develops vaccines to combat seasonal and pandemic influenza. Its primary product, RedeeFlu, is a nasal spray vaccine designed to protect against influenza, utilizing a live, single replication virus that has a portion of the M2 segment deleted. This innovative approach allows for effective prevention of influenza and supports healthcare professionals in controlling potential pandemics. The company is actively engaged in clinical-stage vaccine development to address both seasonal influenza and emerging respiratory threats.

Isomark, LLC, founded in 2005 and based in Madison, Wisconsin, specializes in non-invasive breath monitoring technology aimed at detecting life-threatening infections in both humans and animals. The company has developed a patented breath analyzer called Canary, which measures and analyzes isotopic biomarkers in exhaled CO2 samples. This technology enables rapid detection of infections, providing results in as little as 30 seconds, significantly faster than traditional diagnostic methods that may take hours or days. In the agricultural sector, Isomark addresses the pressing issue of bovine respiratory diseases, which affect approximately one million beef cattle annually in the United States, leading to substantial economic losses. By offering real-time monitoring at the Chute site, Isomark's technology enhances animal health management, reduces the need for antibiotics, and ultimately improves meat quality for consumers.

Holos, Inc. is a company that provides a spatial computing platform designed for educators and students to create, organize, and engage in 3D learning environments. The platform functions as a 3D version of traditional presentation software, allowing users to incorporate photos, videos, text, and 3D models into immersive virtual reality spaces. Holos offers a range of tools, including content creation cards for various media types, a collaborative magic table for spatial presentations, and a library of pre-vetted 3D learning experiences. Additionally, the company is focused on developing immersive training tools for individuals in highly technical physical jobs across critical sectors, utilizing no-code tools to facilitate the creation of Augmented Reality training content. Founded in 2015 and based in Madison, Wisconsin, Holos aims to enhance educational and training experiences through innovative technology.

StudyBlue, Inc. is an educational technology company that offers a collaborative learning platform aimed at enhancing student outcomes both in and out of the classroom. Founded in 2006 and based in San Francisco, StudyBlue provides tools that enable students to connect with peers on similar learning paths through a shared library of user-generated content. The platform includes features such as digital storage for notes, personalized practice quizzes, and crowdsourced study guides, allowing students to create, share, and compare study materials. This approach supports a flexible learning experience, accessible across web and mobile platforms. In December 2008, the company changed its name from The Class Connection, LLC to StudyBlue, Inc., and it became a subsidiary of Chegg, Inc. in July 2018.

FluGen, Inc. is a biopharmaceutical company focused on the prevention and treatment of influenza and other respiratory pathogens. Founded in 2007 and based in Madison, Wisconsin, FluGen develops vaccines to combat seasonal and pandemic influenza. Its primary product, RedeeFlu, is a nasal spray vaccine designed to protect against influenza, utilizing a live, single replication virus that has a portion of the M2 segment deleted. This innovative approach allows for effective prevention of influenza and supports healthcare professionals in controlling potential pandemics. The company is actively engaged in clinical-stage vaccine development to address both seasonal influenza and emerging respiratory threats.

Madison Vaccines, Inc. is a biopharmaceutical company based in the United States that specializes in developing therapeutic plasmid DNA vaccines targeting prostate cancer and bone metastases. The company is focused on creating two distinct vaccines designed for patients with prostate cancer, along with a diagnostic test aimed at identifying those who would benefit most from these therapies. Madison Vaccines' immune-activating therapies work by stimulating the immune system to eliminate residual tumor cells, thereby preventing the progression to bone metastases and delaying the need for more invasive treatments such as castration therapies. This approach aims to improve patient outcomes and enhance quality of life by facilitating earlier interventions in the cancer treatment process.

StudyBlue, Inc. is an educational technology company that offers a collaborative learning platform aimed at enhancing student outcomes both in and out of the classroom. Founded in 2006 and based in San Francisco, StudyBlue provides tools that enable students to connect with peers on similar learning paths through a shared library of user-generated content. The platform includes features such as digital storage for notes, personalized practice quizzes, and crowdsourced study guides, allowing students to create, share, and compare study materials. This approach supports a flexible learning experience, accessible across web and mobile platforms. In December 2008, the company changed its name from The Class Connection, LLC to StudyBlue, Inc., and it became a subsidiary of Chegg, Inc. in July 2018.

Isomark, LLC, founded in 2005 and based in Madison, Wisconsin, specializes in non-invasive breath monitoring technology aimed at detecting life-threatening infections in both humans and animals. The company has developed a patented breath analyzer called Canary, which measures and analyzes isotopic biomarkers in exhaled CO2 samples. This technology enables rapid detection of infections, providing results in as little as 30 seconds, significantly faster than traditional diagnostic methods that may take hours or days. In the agricultural sector, Isomark addresses the pressing issue of bovine respiratory diseases, which affect approximately one million beef cattle annually in the United States, leading to substantial economic losses. By offering real-time monitoring at the Chute site, Isomark's technology enhances animal health management, reduces the need for antibiotics, and ultimately improves meat quality for consumers.

Madison Vaccines, Inc. is a biopharmaceutical company based in the United States that specializes in developing therapeutic plasmid DNA vaccines targeting prostate cancer and bone metastases. The company is focused on creating two distinct vaccines designed for patients with prostate cancer, along with a diagnostic test aimed at identifying those who would benefit most from these therapies. Madison Vaccines' immune-activating therapies work by stimulating the immune system to eliminate residual tumor cells, thereby preventing the progression to bone metastases and delaying the need for more invasive treatments such as castration therapies. This approach aims to improve patient outcomes and enhance quality of life by facilitating earlier interventions in the cancer treatment process.

Silatronix, Inc. specializes in the development of organosilicon (OS) compounds and formulations for use in energy storage devices, particularly in rechargeable and non-rechargeable lithium-ion batteries. Founded in 2007 and based in Madison, Wisconsin, the company focuses on creating patented materials that enhance battery performance by extending cell life, increasing capacity, and allowing higher charge voltages. Silatronix's technology combines expertise in organosilicon compounds and nanostructured electrodes, making its products suitable for a variety of applications, including portable electronics, electric vehicles, and utility-scale energy storage. The company's innovations support advancements in battery technology, contributing to more efficient and effective energy solutions.

NeuWave Medical, founded in 2004 and headquartered in Madison, Wisconsin, specializes in the development of energy-based minimally invasive medical devices designed to treat various serious medical conditions. The company's founders, both engineers and physician-scientists, leverage their expertise to identify clinical needs and create effective solutions that prioritize safety and efficacy. NeuWave Medical aims to produce high-quality devices that are preferred by leading physicians and medical centers globally.

Cellular Dynamics International Inc., (CDI) is a developer and manufacturer of fully functioning cells in industrial quantities to precise specifications. CDI's proprietary products include true human cells in multiple cell types (iCell products), human induced pluripotent stem cells (iPSCs) and custom iPSCs and iCell products (MyCell Products). CDI's products provide standardized, easy-to-use, cost-effective access to the human cell, the smallest fully functioning operating unit of human biology. Customers use our products, among other purposes, for drug discovery and screening, to test the safety and efficacy of their small molecule and biological drug candidates, for stem cell banking, and in the research and development of cellular therapeutics.

NeuWave Medical, founded in 2004 and headquartered in Madison, Wisconsin, specializes in the development of energy-based minimally invasive medical devices designed to treat various serious medical conditions. The company's founders, both engineers and physician-scientists, leverage their expertise to identify clinical needs and create effective solutions that prioritize safety and efficacy. NeuWave Medical aims to produce high-quality devices that are preferred by leading physicians and medical centers globally.

Deltanoid Pharmaceuticals, Inc. is a biopharmaceutical company based in Madison, Wisconsin, dedicated to the research, development, and commercialization of therapies for various human diseases, particularly focusing on renal diseases, osteoporosis, and skin conditions. Founded in 1999, the company specializes in vitamin D analogs and related compounds, aiming to advance selected therapies through the early stages of drug development. Notable products include DP001, designed for treating secondary hyperparathyroidism in chronic kidney disease patients undergoing hemodialysis, and DP006 for acne treatment. Deltanoid seeks partnerships for the later stages of development and commercialization, and it currently has an agreement with Novadiol, Inc. to develop a vitamin D therapy. Through its innovative approach, the company aims to enhance health outcomes for patients by unlocking the potential of vitamin D receptor-targeted therapies.

Mithridion, Inc. is a biopharmaceutical company based in Madison, Wisconsin, that specializes in discovering and developing small molecule drugs aimed at addressing unmet medical needs associated with central nervous system disorders. Founded in 2004, the company focuses primarily on serious chronic neurodegenerative diseases, including Alzheimer's disease and schizophrenia. Its drug portfolio features candidates designed for treating cognitive impairments and blocking disease processes in conditions such as Progressive Supranuclear Palsy. Notable projects include MCD-386CR, which targets neurodegenerative diseases, and MCD-386/glycopyrrolate, aimed at preventing Alzheimer's in genetically defined presymptomatic mutation carriers. Additionally, the company is developing MI-08-016/035 for common neurodegenerative diseases and MI-10-022 to address significant unmet needs in schizophrenia.

OpGen, Inc. is a precision medicine company focused on developing molecular diagnostics and informatics to address infectious diseases. Headquartered in Gaithersburg, Maryland, OpGen offers a range of products designed to provide clinicians with rapid and actionable information regarding life-threatening infections, ultimately aiming to enhance patient outcomes and reduce the spread of multidrug-resistant organisms (MDROs). Its key offerings include the Acuitas AMR Gene Panel, which detects bacterial nucleic acids and genetic markers of antimicrobial resistance, and the QuickFISH and PNA FISH products for pathogen identification in blood cultures. Additionally, OpGen provides the Acuitas Lighthouse informatics system, a cloud-based platform that integrates clinical lab results with patient and hospital data to support the management of antimicrobial-resistant infections. The company collaborates with the New York State Department of Health to develop solutions for detecting and tracking such infections in healthcare settings. Established in 2001, OpGen continues to innovate in addressing the critical challenge of antibiotic resistance through its advanced molecular microbiology solutions.

Roche NimbleGen specializes in providing a range of products and services for the life science research market, particularly in DNA sequencing and microarray technology. The company offers the SeqCap EZ system, which allows for exome enrichment in a single test tube, along with various design options and reagents to facilitate workflow. Additionally, Roche NimbleGen has developed the SeqCap Epi system for DNA methylation assessment at single-base resolution, and it supplies preparation and adapter kits for library construction. Their proprietary Maskless Array Synthesis technology enables the creation of custom high-density DNA arrays, enhancing the quality and data yield of sequencing efforts. The company also provides a suite of DNA microarray products for applications such as comparative genomic hybridization and gene expression analysis, alongside technical support services. Founded in 1999 and based in Madison, Wisconsin, Roche NimbleGen operates as a subsidiary of Roche Holding AG.

Roche NimbleGen specializes in providing a range of products and services for the life science research market, particularly in DNA sequencing and microarray technology. The company offers the SeqCap EZ system, which allows for exome enrichment in a single test tube, along with various design options and reagents to facilitate workflow. Additionally, Roche NimbleGen has developed the SeqCap Epi system for DNA methylation assessment at single-base resolution, and it supplies preparation and adapter kits for library construction. Their proprietary Maskless Array Synthesis technology enables the creation of custom high-density DNA arrays, enhancing the quality and data yield of sequencing efforts. The company also provides a suite of DNA microarray products for applications such as comparative genomic hybridization and gene expression analysis, alongside technical support services. Founded in 1999 and based in Madison, Wisconsin, Roche NimbleGen operates as a subsidiary of Roche Holding AG.

Realta Fusion is focused on developing fusion energy technology aimed at producing industrial heat and power. The company leverages advancements in superconducting materials, plasma physics, and computing power to create a straightforward linear fusion reactor design. This innovative approach allows Realta Fusion to utilize abundant fuel sources, offering a zero-carbon solution for heat and power generation. By minimizing capital expenditures associated with power plant construction, the company positions itself as a provider of sustainable energy solutions.